97 related articles for article (PubMed ID: 15482812)
1. Dopamine transporter network and pathways.
Maiya R; Mayfield RD
Int Rev Neurobiol; 2004; 61():79-96. PubMed ID: 15482812
[No Abstract] [Full Text] [Related]
2. Unraveling neuronal dopamine transporter mechanisms with rotating disk electrode voltammetry.
Schenk JO; Wright C; Bjorklund N
J Neurosci Methods; 2005 Apr; 143(1):41-7. PubMed ID: 15763135
[TBL] [Abstract][Full Text] [Related]
3. Fragmentation pathway of dopamine transporter ligands: N-substituted-2beta-carbomethoxy-3beta-phenylnortropane derivatives.
Mavel S; Abarbri M; Frangin Y; Duchène A; Emond P
J Pharm Biomed Anal; 2004 Apr; 35(1):193-8. PubMed ID: 15030894
[TBL] [Abstract][Full Text] [Related]
4. Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism.
Sorkina T; Hoover BR; Zahniser NR; Sorkin A
Traffic; 2005 Feb; 6(2):157-70. PubMed ID: 15634215
[TBL] [Abstract][Full Text] [Related]
5. Proline mutations induce negative-dosage effects on uptake velocity of the dopamine transporter.
Lin Z; Uhl GR
J Neurochem; 2005 Jul; 94(1):276-87. PubMed ID: 15953370
[TBL] [Abstract][Full Text] [Related]
6. Methylphenidate analogs with behavioral differences interact differently with arginine residues on the dopamine transporter in rat striatum.
Volz TJ; Bjorklund NL; Schenk JO
Synapse; 2005 Sep; 57(3):175-8. PubMed ID: 15945061
[TBL] [Abstract][Full Text] [Related]
7. The dopamine transporter: role in neurotoxicity and human disease.
Bannon MJ
Toxicol Appl Pharmacol; 2005 May; 204(3):355-60. PubMed ID: 15845424
[TBL] [Abstract][Full Text] [Related]
8. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate.
Chen R; Han DD; Gu HH
J Neurochem; 2005 Jul; 94(2):352-9. PubMed ID: 15998286
[TBL] [Abstract][Full Text] [Related]
9. The serotonin transporter: a vehicle to elucidate pulmonary hypertension?
Weir EK; Hong Z; Varghese A
Circ Res; 2004 May; 94(9):1152-4. PubMed ID: 15142967
[No Abstract] [Full Text] [Related]
10. Characterization of serotonin transporter in blood lymphocytes of rats. Modulation by in vivo administration of mitogens.
Cedeño N; Urbina M; Obregón F; Lima L
J Neuroimmunol; 2005 Feb; 159(1-2):31-40. PubMed ID: 15652400
[TBL] [Abstract][Full Text] [Related]
11. Computer-assisted design of dopamine transporter ligands.
Loew GH; Villar HO; Maguire PA; Davies MF
NIDA Res Monogr; 1993; 134():165-77. PubMed ID: 8289877
[No Abstract] [Full Text] [Related]
12. Antioxidative activities of novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter.
Kimura M; Masuda T; Yamada K; Kawakatsu N; Kubota N; Mitani M; Kishii K; Inazu M; Kiuchi Y; Oguchi K; Namiki T
Bioorg Med Chem Lett; 2004 Aug; 14(16):4287-90. PubMed ID: 15261288
[TBL] [Abstract][Full Text] [Related]
13. Technetium-99m labelled integrated tropane-BAT as a potential dopamine transporter tracer.
Cleynhens BJ; de Groot TJ; Vanbilloen HP; Kieffer D; Mortelmans L; Bormans GM; Verbruggen AM
Bioorg Med Chem; 2005 Feb; 13(4):1053-8. PubMed ID: 15670913
[TBL] [Abstract][Full Text] [Related]
14. Wrestling with restless legs.
Sloand JA
Sleep Med; 2005 Jul; 6(4):295-6. PubMed ID: 15978512
[No Abstract] [Full Text] [Related]
15. Synthesis and pharmacology of 6-substituted benztropines: discovery of novel dopamine uptake inhibitors possessing low binding affinity to the dopamine transporter.
Simoni D; Rossi M; Bertolasi V; Roberti M; Pizzirani D; Rondanin R; Baruchello R; Invidiata FP; Tolomeo M; Grimaudo S; Merighi S; Varani K; Gessi S; Borea PA; Marino S; Cavallini S; Bianchi C; Siniscalchi A
J Med Chem; 2005 May; 48(9):3337-43. PubMed ID: 15857139
[TBL] [Abstract][Full Text] [Related]
16. Voltammetric assessment of dopamine clearance in the absence of the dopamine transporter: no contribution of other transporters in core or shell of nucleus accumbens.
Mateo Y; Budygin EA; John CE; Banks ML; Jones SR
J Neurosci Methods; 2004 Dec; 140(1-2):183-7. PubMed ID: 15589348
[TBL] [Abstract][Full Text] [Related]
17. Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra.
Paris I; Martinez-Alvarado P; Perez-Pastene C; Vieira MN; Olea-Azar C; Raisman-Vozari R; Cardenas S; Graumann R; Caviedes P; Segura-Aguilar J
J Neurochem; 2005 Mar; 92(5):1021-32. PubMed ID: 15715653
[TBL] [Abstract][Full Text] [Related]
18. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.
Ukairo OT; Bondi CD; Newman AH; Kulkarni SS; Kozikowski AP; Pan S; Surratt CK
J Pharmacol Exp Ther; 2005 Aug; 314(2):575-83. PubMed ID: 15879005
[TBL] [Abstract][Full Text] [Related]
19. Modulation of monoamine transporter expression and function by repetitive transcranial magnetic stimulation.
Ikeda T; Kurosawa M; Uchikawa C; Kitayama S; Nukina N
Biochem Biophys Res Commun; 2005 Feb; 327(1):218-24. PubMed ID: 15629452
[TBL] [Abstract][Full Text] [Related]
20. Role of C-terminal region in the functional regulation of rat serotonin transporter (SERT).
Mochizuki H; Amano T; Seki T; Matsubayashi H; Mitsuhata C; Morita K; Kitayama S; Dohi T; Mishima HK; Sakai N
Neurochem Int; 2005 Jan; 46(2):93-105. PubMed ID: 15627510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
